<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04310202</url>
  </required_header>
  <id_info>
    <org_study_id>Doc-00066211</org_study_id>
    <nct_id>NCT04310202</nct_id>
  </id_info>
  <brief_title>Multi-Centre Study on the Performance of the Ponto BHX Implant System (in Adult Patients)</brief_title>
  <official_title>A Prospective Multi-Centre Study on the Performance of the Ponto BHX Implant System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oticon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oticon Medical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-centre study funded by Oticon Medical AB will be conducted at seven hospitals&#xD;
      across Europe (UK, Spain, Denmark). Patients with a hearing loss and that are already planned&#xD;
      for treatment with a percutaneous (through the skin) bone-anchored hearing system (BAHS) will&#xD;
      be included in the study. A total of 50 patients will be included in the study.&#xD;
&#xD;
      The purpose of this study is to investigate the rate of successful BAHS use after&#xD;
      implantation of the Ponto Biohelix (BHX) Implant system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-centre study funded by Oticon Medical AB will be conducted at seven hospitals&#xD;
      across Europe (UK, Spain, Denmark). Patients with a hearing loss and that are already planned&#xD;
      for treatment with a percutaneous (through the skin) bone-anchored hearing system (BAHS) will&#xD;
      be included in the study. A total of 50 patients will be included in the study.&#xD;
&#xD;
      The purpose of this study is to investigate the rate of successful BAHS use after&#xD;
      implantation of the Ponto BHX Implant system. The implant, coupled to a skin-penetrating&#xD;
      abutment, is implanted in the bone behind the ear and is later loaded with a sound processor&#xD;
      which transforms sound waves to sound vibrations that can be sent directly to the inner ear&#xD;
      via the skull bone. The primary objective of this study is to investigate the proportion of&#xD;
      implant/abutment complexes providing a reliable anchorage for a sound processor, 3 months&#xD;
      after implantation/surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Implant/abutment complex capability to provide a reliable Anchorage for a sound processor</measure>
    <time_frame>3 months after implant surgery</time_frame>
    <description>The variables assessed to determine reliable anchorage in the study are implant survival and stability, skin reactions, skin over-growth and pain preventing use of the sound processor. For a positive outcome of the primary endpoint (reliable anchorage), the implant should be in place and stable. without any adverse skin reactions or skin over-growth and pain preventing usage of the sound processor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant/abutment complex capability to provide reliable anchorage for sound processor</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>The variables assessed to determine reliable anchorage in the study are implant survival and stability, skin reactions, skin over-growth and pain preventing use of the sound processor. For a positive outcome of the primary endpoint (reliable anchorage), the implant should be in place and stable without any adverse skin reactions or skin over-growth and pain preventing usage of the sound processor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survival</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Implant survival will be assessed by the investigator by means of a Yes/No question: Implant/abutment complex in place [Yes/No]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant stability</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Clinical assessment of implant stability by the investigator by means of a Yes/No question: Implant stable [Yes/No]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holgers score ratings</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Distribution of Holgers score ratings (scale 0-4) where a higher score corresponds to a poorer outcome, assigned by investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPS (Inflammation, Pain, Skin height) scores</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Distribution of IPS (Inflammation [total score 0-4], Pain [score 0-2], Skin height [score 0-2]) scores assigned by investigator. The IPS score is presented as [Ix Px Sx] with x being the individual score for each parameter. A higher score corresponds to a poorer outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived presence of pain around implant/abutment</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Assessment of presence of patient-perceived pain by means of a Yes/No question to the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived magnitude of pain around implant/abutment</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Assessment of magnitude of patient-perceived pain using a numerical rating scale (NRS) (range 0-10) where a higher rating corresponds to a poorer outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived presence of numbness around implant/abutment</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Assessment of presence of patient-perceived numbness by means of a Yes/No question to the subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived magnitude of numbness around implant/abutment</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Assessment of magnitude of patient-perceived numbness using a numerical rating scale (NRS) (range 0-10) where a higher rating corresponds to a poorer outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin/soft tissue overgrowth</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Skin overgrowth over implant/abutment complex judged by the investigator by means of a Yes/No question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of surgery</measure>
    <time_frame>At implant surgery</time_frame>
    <description>Length of surgery measured in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound dehiscence</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Prevalence of wound dehiscence measured as millimeters of dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound healing time</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Average healing time [days] from surgery when the wound is considered healed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant/abutment usage</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Mean hours of use of a sound processor on the implant/abutment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective benefit after implant surgery</measure>
    <time_frame>At screening visit (visit before surgery)</time_frame>
    <description>Abbreviated Profile Hearing Aid Benefit (APHAB) questionnaire score (1-99) where a global higher score corresponds to a poorer outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective benefit after implant surgery</measure>
    <time_frame>6 months after implant surgery</time_frame>
    <description>Abbreviated Profile Hearing Aid Benefit (APHAB) questionnaire score (1-99) where a global higher score corresponds to a poorer outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective benefit after implant surgery</measure>
    <time_frame>3 months after implant surgery</time_frame>
    <description>Glasgow Benefit Inventory (GBI) questionnaire score (-100 to +100) where [-100] means maximum adverse effect, [0] means no effect, and [+100] means maximum positive effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective benefit after implant surgery</measure>
    <time_frame>12 months after implant surgery</time_frame>
    <description>Glasgow Benefit Inventory (GBI) questionnaire score (-100 to +100) where [-100] means maximum adverse effect, [0] means no effect, and [+100] means maximum positive effect</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcome</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Occurrence and severity of adverse events related to the investigational device and corresponding procedures</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <description>In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and additional follow-up visits after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Abbreviated Profile of Hearing Aid Benefit (APHAB)</intervention_name>
    <description>An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on two occasions.</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Glasgow Benefit Inventory (GBI)</intervention_name>
    <description>An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on two occasions.</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional follow-up visits after surgery</intervention_name>
    <description>There are 1-2 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to participating clinics who meet clinical indications for surgical&#xD;
        intervention with a bone anchored hearing system&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Patients indicated for surgical intervention with a bone anchored hearing system&#xD;
             according to local clinic's standard guidelines&#xD;
&#xD;
          -  Adequate bone quality to allow for a Ponto BHX implant insertion, as judged by the&#xD;
             investigator, and an expected bone thickness above 3 mm, where no complications during&#xD;
             surgery are expected&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing re-implantation&#xD;
&#xD;
          -  Patients who are unable or unwilling to follow investigational&#xD;
             procedures/requirements, e.g. to complete quality of life scales.&#xD;
&#xD;
          -  Diseases or treatments known to compromise the bone quality at the implant site, e.g.&#xD;
             radiotherapy, osteoporosis, diabetes mellitus&#xD;
&#xD;
          -  Known conditions (e.g. uncontrolled diabetes) that could jeopardize skin condition and&#xD;
             wound healing over time as judged by the investigator&#xD;
&#xD;
          -  Any other known condition that the investigator determines could interfere with&#xD;
             compliance or study assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupan Banga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Birmingham NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sukhi Singh, PhD</last_name>
    <phone>0046734219323</phone>
    <email>suin@oticonmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dupont Hougaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Foghsgaard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>San Sebasti√°n</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Altuna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martinez-Beneyto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Royo-Lopez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pai</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

